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396Objective: Doxorubicin is a widely used chemotherapy drug, but its application is associated with cardiotox-
icity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced
cardiac failure. Angiotensin-converting enzyme inhibitors are commonly used as cardioprotective agents and
have recently been shown in clinical studies to be efficacious in the prevention of anthracycline-induced heart
failure. This study evaluated a mechanism for these protective effects by testing the ability of the angiotensin-
converting enzyme inhibitor enalapril to preserve mitochondrial function in a model of chronic doxorubicin
treatment in rats.
Methods: Sprague Dawley rats were divided into 3 groups and followed for a total of 10 weeks: (1) control-
untreated, (2) doxorubicin treated, and (3) doxorubicinþ enalapril treated. Doxorubicin was administered via
intraperitoneal injection at weekly intervals from weeks 2 to 7. Enalapril was administered in the drinking water
of the doxorubicinþenalapril group for the study duration.
Results: Doxorubicin treatment produced a significant loss in left ventricular contractility (P<.05), decrease in
mitochondrial function via impairment of state-3 respiration, decrease in the cytosolic fraction of adenosine
triphosphate, and up-regulation of free radical production. Enalapril significantly attenuated the decrease in per-
cent fractional shortening (P<.05) and prevented the doxorubicin-associated reduction in respiratory efficiency
and cytosolic adenosine triphosphate content (P<.05). Enalapril also abolished the robust doxorubicin-induced
increase in free radical formation.
Conclusions: Administration of enalapril attenuates doxorubicin-induced cardiac dysfunction via preservation
of mitochondrial respiratory efficiency and reduction in doxorubicin-associated free radical generation.
(J Thorac Cardiovasc Surg 2011;142:396-403)Supplemental material is available online.
Doxorubicin, an anthracycline, is a widely used cytotoxic
agent for the treatment of human neoplasms, such as leuke-
mias and Hodgkin’s lymphoma. However, administration of
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The Journal of Thoracic and Cardiovascular Surgleading to congestive heart failure that almost invariably de-
velops in patients receiving cumulative doses of doxorubi-
cin more than 550 mg/m2.1 As a result of doxorubicin
therapy, a growing number of patients in the United States
survive childhood and adult cancers only to develop severe
cardiac dysfunction after treatment.2 These patients have
few surgical options for treatment because they have a com-
bination of both dilated and restrictive cardiomyopathies,
and make poor heart transplant candidates because of their
history of cancer. Development of medical therapies that aid
in the management of cardiac dysfunction is thus para-
mount for the long-term survival of these individuals.
Several previous studies have implicated free radical for-
mation and oxidative stress as central mechanisms underly-
ing the cardiotoxic effects of doxorubicin.3 As a result,
many experimental drug treatments to ameliorate cardio-
toxicity of doxorubicin have focused on the protective ef-
fects of antioxidants and metal chelators, which minimize
free radical damage.4 Although these substances have
shown some benefit, they are difficult to administer because
of the challenge of achieving constant plasma concentra-
tions of antioxidant drugs and their poor uptake by the
heart.5ery c August 2011
Abbreviations and Acronyms
ACE ¼ angiotensin-converting enzyme
ADP ¼ adenosine diphosphate
ATP ¼ adenosine triphosphate
ETC ¼ electron transport chain
FRL ¼ free radical leak
NS ¼ not significant
P/M ¼ pyruvate/malate
RCR ¼ respiratory control ratio
ROS ¼ reactive oxygen species
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a class of drugs that are routinely administered in the clinic
and have clearly shown positive therapeutic profiles for the
treatment of heart failure caused by a number of cardiovas-
cular diseases.6 ACE inhibitors possess free radical scaven-
ger and antioxidant properties,7 and have recently been
shown in 2 prospective clinical studies to be efficacious in
the prevention of anthracycline-induced heart failure
when administered early after chemotherapy regimens.8,9
Administration of ACE inhibitors in these trials and
preclinical studies has not been linked with an increased
rate of recurrent malignancy.1,10 However, only a limited
number of studies have investigated the mechanisms by
which ACE inhibition can prevent anthracycline-induced
cardiotoxicity.7,11 The potential effects ACE inhibitors
may have on prevention of anthracycline-induced mito-
chondrial dysfunction remain unknown. To answer these
questions, this study aimed to (1) investigate in vivo the pos-
sible protective effects of the ACE inhibitors (enalapril)
against doxorubicin-induced cardiac toxicity in a longitudi-
nal model of treatment and (2) determine whether the im-
proved cardiac function from ACE inhibitor therapy is
due to improved mitochondrial function and reduced free
radical generation. Our results show that the concurrent ad-
ministration of ACE inhibitors with doxorubicin treatment
not only ameliorates cytotoxic effects of doxorubicin but
also prevents doxorubicin-induced free radical formation
and preserves mitochondrial respiratory efficiency and cel-
lular adenosine triphosphate (ATP) content.
MATERIALS AND METHODS
Animals
Twenty-four female Sprague Dawley rats at approximately 10 weeks of
age were obtained from Charles River Laboratories (Wilmington, Mass).
The animals were divided into 3 groups: a) control-untreated (n ¼ 8), b)
doxorubicin treated (Dox) (n ¼ 8), and c) doxorubicinþ enalapril treated
(DE) (n¼ 8). BothDox andDE groups received doxorubicin at a cumulative
dose of 25 mg/kg administered weekly via intraperitoneal injection for 6
weeks. Enalapril pretreatment for the DE group was started 1 week before
administration of the first doxorubicin injection and continued throughout
the study and for an additional 3 weeks after the last doxorubicin injection
(Figure1,A).Thedosageofenalaprilwascalculatedon thebasisof apreviousThe Journal of Thoracic and Castudy by Sanbe and colleagues12 and set at a dose of 10 mg/kg/d for each
animal as previously described.12 A detailed description is included in the
Supplemental Materials and Methods.
Assessment of Cardiac Function
Echocardiography studies were performed before treatment and imme-
diately before animal sacrifice to determine left ventricular fractional short-
ening, using a 14.7-MHz transducer on a Sequoia C512 echocardiography
system (Siemens, Malvern, Pa). A detailed description is included in the
Supplemental Materials and Methods.
Tissue Histology
Heart and liver specimens were fixed in 4% paraformaldehyde and
stainedwith hematoxylin–eosin for analysis by lightmicroscopy.A detailed
description is included in the Supplemental Materials and Methods.
EnzymaticMeasurement of Caspase-3 andCaspase-9
Activities
Caspase-3 and caspase-9 activities were measured using fluorometric
protease assay kits: Caspase-3/CPP32 and Caspase-9/Mch6 (Biovision,
Mountain View, Calif). A complete description is included in the Supple-
mental Materials and Methods.
Mitochondrial and Cytosolic Isolation
Mitochondrial and cytosolic protein fractions were isolated using differ-
ential centrifugation as previously described. A detailed description is in-
cluded in the Supplemental Materials and Methods.
Mitochondrial Respiration and H2O2 Generation
Mitochondrial oxygen consumption was measured at 37C by polarog-
raphy, with a Clark-type oxygen electrode (Oxytherm, Hansatech, Norfolk,
UK) under identical conditions (same mitochondria, buffer composition,
and substrate concentrations) to H2O2 production measurements. The
rate of mitochondrial H2O2 production was assayed in freshly isolated
mitochondria by a fluorometric method described by Barja.13 A complete
description is included in the Supplemental Materials and Methods.
Adenosine Triphosphate Content
Cytosolic homogenate isolated from heart was used immediately after
isolation to determine ATP content using a bioluminescence ATP kit
from Sigma-Aldrich Inc (St Louis,Mo). A complete description is included
in the Supplemental Materials and Methods.
Statistical Analysis
Data were analyzed using a 1-way analysis of variance with Newman–
Keuls post hoc comparison. All data are represented as average standard
error of the mean.RESULTS
Rats were studied longitudinally over 10 weeks (Figure 1,
A). Control animals were compared with the Dox and DE
groups. There was a 100% survival in both control and
DE groups up to 10 weeks. In contrast, the Dox group expe-
rienced only a 75% survival (2 deaths) (Figure 1, B). These
data show that a 10-week model of doxorubicin administra-
tion causes significant toxicity resulting in mortality and
validates the time course for intervention.
Doxorubicin treatmentwas observed to cause a significant
decrease in cardiac function, as quantified by depressedrdiovascular Surgery c Volume 142, Number 2 397
FIGURE 1. Study design and animal survival. A, Schematic for study design. B, Kaplan–Meier survival curve for control, Dox, and DE animals during the
duration of the study. P ¼ NS. Dox, Doxorubicin; IP, intraperitoneal; DE, doxorubicinþenalapril.
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phy (baseline before Dox treatment: 38.62%  0.77%,
post-treatment control: 39.28%  0.83% vs Dox: 24.92%
 3.08%, P<.05). Enalapril treatment significantly attenu-
ated loss of systolic function in the DE group (DE: 31.42%
 1.06%, P<.05 vs Dox) (Figure 2, A, B). These findings
confirm previous findings, including 2 recent human clinical
studies showing that simultaneous administration of enalap-
ril can significantly blunt the deleterious cardiotoxic effects
of doxorubicin on heart function.7-9,14
Doxorubicin not only reduced contractility in treated an-
imals but also caused pathologic changes as observed by
histology. Histologic sections of the heart in Dox animals
showed numerous scattered foci of myofibrillar degenera-
tion with associated contraction bands (Figure 2, C). By
comparison, DE hearts showed only elongated cardiomyo-
cytes. The livers in both Dox and DE groups showed gross
enlargement, thickened and inflamed capsules, indications
of venous congestion, and hepatocyte cytopathology with
regenerative changes.
The decline in cardiac function and histologic changes of
the myocardium caused by doxorubicin are not fully under-
stood. Apoptosis has been implicated in doxorubicin-
induced cardiac dysfunction.15 We found that apoptosis
levels as measured by caspase-3 activity in the cytosol of
Dox and DE rat hearts were significantly higher than those
in control animals (control: 122.2  8.7 FU/mg protein vs398 The Journal of Thoracic and Cardiovascular SurgDox: 165.5  19.8 FU/mg protein vs DE: 169.0  9.2
FU/mg protein, P<.05). Caspase-9 activity was also ele-
vated in Dox and DE rats compared with controls (control:
196.4  15.1 FU/mg protein vs Dox: 251.6  11.8 FU/mg
protein vs DE: 252.9  16.0 FU/mg protein, P < .05)
(Figure 3, A). Comparison of caspase-3 activity with that
of caspase-9 revealed a significant positive correlation
(r ¼ 0.65, P<.01) (Figure 3, B), providing evidence for in-
duction of the mitochondrial-mediated pathway of apopto-
sis. These data corroborate previous findings that apoptosis
levels are increased in the myocardium by doxorubicin and
show that the increase in cardiac apoptosis is not signifi-
cantly attenuated by enalapril.
Because enalapril was observed to improve systolic func-
tion after doxorubicin treatment but did not prevent apopto-
sis, we sought to determine whether protection against
anthracycline-induced toxicity by ACE inhibitors was due
to an alternative mechanism. Several recent clinical studies
have suggested that ACE inhibitionmay be efficacious in the
prevention of anthracycline-induced heart failure by protec-
tion of mitochondrial function.8,9 However, these reports
did not show causality between antioxidant properties of
enalapril and improvement in systolic function in patients
post-chemotherapy. To test whether doxorubicin signifi-
cantly affects mitochondrial processes and enalapril can
ameliorate these changes, we evaluated oxygen consump-
tion in intact mitochondria isolated from the hearts ofery c August 2011
FIGURE 2. Doxorubicin treatment results in a significant loss of heart function and myofibrillar degeneration in rats, whereas enalapril significantly at-
tenuates these changes. A, Left ventricular fractional shortening was measured by echocardiography before animal sacrifice. Representative echocardio-
grams are shown for control, Dox, and DE animals 10 weeks after infarction. B, Statistical analysis of echocardiographic measures. Error bars represent
the standard error of the mean (SEM). *,#P<.05. *Significantly different compared with Dox andDE groups. #Significantly different compared with control
and DE groups. C, Enalapril treatment prevents significant myofibrillar degeneration with contraction band formation in doxorubicin-treated hearts but does
not prevent liver cytopathic changes. Compared with control hearts (i), Dox hearts (n ¼ 3) (ii) exhibited numerous contraction bands (arrows) with nearby
myofibrillar degeneration (arrowheads), whereas only myocyte elongation is seen in the DE heart (iii). Compared with control livers (iv), the Dox and DE
livers (v and vi) showed capsular fibrosis and inflammation [asterisks], hepatocyte swelling, and pleiomorphic cords of hepatocytes.DOX,Doxorubicin;DE,
doxorubicinþenalapril.
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(P/M) was used to simulate state 4, the inactive state of mi-
tochondria, and addition of P/Mwith adenosine diphosphate
(ADP) as substrates was used to simulate state 3, the active
state of mitochondria.16
Treatment with doxorubicin alone (Dox group) de-
creased oxygen consumption levels in both states 3 and
4 (Figure 4, A). This effect was particularly pronounced
in state 3, the ATP producing a state of mitochondria
where oxygen consumption typically increases robustly.
Although doxorubicin alone decreased mitochondrial oxy-
gen consumption by 2.5-fold in state 3 compared with
control animals, the addition of enalapril (DE group) com-
pletely reversed this effect (control: 47.66  4.15 nmoles
O2/min mg protein, Dox: 18.94  4.67 nmoles O2/min mg
protein, DE: 50.44  6.90 nmoles O2/min mg protein,
P<.05 for control vs Dox and DE vs Dox, P ¼ not sig-
nificant [NS] for control vs DE) (Figure 4, A). Doxorubi-
cin also significantly lowered oxygen consumption in state
4 mitochondria, the inactive state of mitochondria in
which ADP phosphorylation does not occur. As with state
3, enalapril completely abolished this effect. These find-
ings suggest that enalapril can prevent mitochondrial dys-
function caused by doxorubicin toxicity by allowingThe Journal of Thoracic and Camitochondrial state 3 and state 4 respiration to be main-
tained at control levels.
Correlation of active to inactive mitochondrial coupling
was further determined by calculating the respiratory con-
trol ratio (RCR), defined as state 3 oxygen consumption/
state 4 oxygen consumption. By calculating the RCR, we
found that doxorubicin not only decreased inactive (state
4) and active (state 3) mitochondrial respiration but also
lowered the functional coupling of oxygen consumption
at baseline (state 4) with the efficiency of energy production
by ADP phosphorylation (state 3). Addition of enalapril sig-
nificantly ameliorated the disproportional decrease in RCR
and impairment of mitochondrial metabolic activity in-
duced by doxorubicin (control RCR: 6.747  0.428, Dox
RCR: 3.666  0.791, DE RCR: 5.458  0.516, P< .05
for control vs Dox, P¼NS for DE vs control) (Figure 4, A).
To test whether impairment of oxidative respiration af-
fected mitochondrial output, we next evaluated ATP pro-
duction in the hearts of animals treated with doxorubicin.
ATP produced by mitochondria is exported into the cytosol
for cellular function. ATP content was therefore measured
in the cytosolic homogenate of heart tissue from animals
in the control, Dox, and DE groups. Total ATP content in
the cytosolic homogenate was found to be significantlyrdiovascular Surgery c Volume 142, Number 2 399
FIGURE 3. Doxorubicin treatment induces up-regulation in caspase-3 and caspase-9 activities in both Dox and DE groups. A, Caspase-3 and caspase-9
activities were measured in ventricular cytosolic fractions using a fluorometric protease assay kit that is based on detection of cleavage of the substrate
DEVD-AFC or LEHD-AFC by caspase-3 and -9, respectively. Error bars represent SEM. *P<.05. *Significantly different compared with Dox and DE
groups. B, Pearson correlation of caspase-3 with caspase-9 activity. Pearson r value is shown in top left corner. Caspase-3 data from all 3 groups were plotted
against caspase-9 data. Correlation was significant, **P<.01. Dox, Doxorubicin; DE, doxorubicinþenalapril.
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animals (control: 27.87  2.37 fmoles ATP/mg protein,
Dox: 14.44  3.92 fmoles ATP/mg protein, P < .05)
(Figure 4, B). The addition of enalapril completely reversed
this effect, increasing the cytosolic ATP content to near con-
trol levels in the DE group of animals (control: 27.87 2.37
fmoles ATP/mg protein, DE: 24.24  1.66 fmoles ATP/mg
protein, P ¼ NS). This outcome suggests that the impair-
ment of mitochondrial respiratory efficiency by doxorubi-
cin results in depletion of ATP for cellular use, and that
enalapril is able to reverse this effect by preserving normal
levels of oxidative respiration.
Finally, because several previous studies have shown that
dysfunction of mitochondrial respiration and production of
ATP are linked to increased generation of reactive oxygen
species (ROS),17 we assessed levels of oxidative stress in
the hearts of control, Dox, and DE animals. ROS production
was measured as the amount of H2O2 released from the
mitochondria in an incubation medium supplemented with
P/M to evaluate total basal mitochondrial ROS genera-
tion.13 Absolute values for basal levels of H2O2 production
were not significantly different among control, Dox, and DE
animals (control: 0.313  0.028 nmoles H2O2/min mg pro-
tein vs Dox: 0.345 0.039 nmoles H2O2/min mg protein vs400 The Journal of Thoracic and Cardiovascular SurgDE: 0.353  0.037 nmoles H2O2/min mg protein, P ¼ NS)
(Figure 5, A). Although these results may seem to suggest
that doxorubicin administration is not associated with in-
creased oxidative stress, these findings actually indicate
the opposite—that free radical generation is elevated in
the hearts of animals treated with doxorubicin. This is due
to the consideration that H2O2 generation is typically pro-
portional to mitochondrial O2 consumption.
20 Because
levels of O2 consumption were observed to be lower in mi-
tochondria of Dox animals compared with that of control
and DE rats (Figure 4, A), we would normally anticipate
H2O2 production in the Dox group to be proportionately
low as well. Thus, elevation of H2O2 production in animals
receiving doxorubicin to levels observed in control and DE
groups indicates significant impairment in the efficiency of
mitochondria of Dox animals to avoid free radical leakage
from the respiratory chain (Figure 5, A).
This is best illustrated by calculation of the free radical
leak (FRL%), which is defined as the proportion of elec-
trons that flow out of sequence in the electron transport
chain (ETC) to reduce O2 to hydrogen peroxide instead of
reaching cytochrome oxidase to reduce O2 to water. Be-
cause 2 electrons are needed to reduce 1 mole of O2 to
hydrogen peroxide, whereas 4 electrons are required toery c August 2011
FIGURE 4. Enalapril prevents mitochondrial respiratory dysfunction and preserves cellular ATP content. A,We determined the effects of doxorubicin and
enalapril on O2 consumption of isolated heart mitochondria. Oxygen consumption was measured during both states 4 and 3 via polarography using a Clark-
type electrode. The RCR, an index of mitochondrial coupling and metabolic efficiency, was calculated by dividing state 3 to state 4 respiration values. Error
bars represent SEM. *,#P<.05. *Significantly different compared with DE group. #Significantly different compared with control and DE groups. B, ATP
content was measured in the cytosolic homogenate using an ATP bioluminescence kit. Cellular ATP content was found to be decreased in the Dox group
compared with the control and DE groups. Error bars represent SEM. *P<.05. *Significantly different compared with control and DE groups. RCR,
Respiratory control ratio; ATP, adenosine triphosphate; DE, doxorubicinþenalapril.
Hiona et al Evolving Technology/Basic Sciencereduce 1 mole of O2 to water, the fraction of electrons that
form ROS may be calculated by dividing the rate of H2O2
production by 2 times the rate of O2 consumption and mul-
tiplying the result by 100.18 Calculation of the FRL%
revealed a significant difference in ETC dysfunction be-
tween control and Dox animals (control: 2.29%  0.27%FIGURE 5. The increase in mitochondrial FRL, induced by doxorubicin, is co
sured H2O2 production in intact mitochondria of control, Dox, and DE animals.
strate for oxidative phosphorylation. P/M was used to study total basal mitochon
was calculated for P/M supplemented mitochondria, by dividing the H2O2 values
to give a percent value. Error bars represent SEM. *P<.05. *Significantly differ
radical leak; ROS, reactive oxygen species; Dox, doxorubicin; DE, doxorubicin
The Journal of Thoracic and Cavs Dox: 3.54%  0.60%, P<.05) (Figure 5, B). Enalapril
treatment abolished ETC dysfunction caused by doxorubi-
cin (DE: 1.98%  0.26%, P<.05 vs Dox). These findings
demonstrate that anthracycline administration causes leak-
age of free radicals, and that enalapril can ameliorate this
negative effect.mpletely abolished with simultaneous administration of enalapril. We mea-
A, Heart mitochondria were obtained and supplemented with P/M as a sub-
drial ROS production. B, The FRL%, an index of mitochondrial efficiency,
by twice the state 4 respiration values, and the result was multiplied by 100
ent compared with control and DE groups. P/M, Pyruvate/malate; FRL, free
þenalapril.
rdiovascular Surgery c Volume 142, Number 2 401
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The efficacy of doxorubicin as an anti-cancer drug has led
to the search for diverse strategies to prevent its cytotoxic ef-
fects.19 Although many candidate compounds have been
tested, surprisingly little research has examined the possible
effect of ACE inhibitors on doxorubicin toxicity. Two recent
clinical studies have demonstrated early treatment of
anthracycline-induced cardiotoxicity with ACE inhibition
significantly ameliorates development of heart failure.8,9
Although the authors of these studies do not present
a definite mechanism for these results, they strongly
postulate the antioxidant properties of enalapril are
a primary mechanism by which ACE inhibition prevents
against anthracycline cardiotoxicity. We demonstrate that
enalapril does have a protective effect on mitochondrial
function in doxorubicin-treated rats by (1) maintaining mi-
tochondrial O2 consumption at control levels, (2) preventing
the depletion of cellular ATP content, and (3) lowering the
mitochondrial FRL.
It is important to recognize that treatment by ACE inhibi-
tion has been shown to have a number of beneficial effects on
the cardiovascular system. These effects include reduction
in mean arterial pressure, preload, and afterload, which con-
tribute toward preservation of cardiac contractility.20 The
systolic improvements observed in animals treatedwith ena-
lapril in this study are almost certainly due in part to the ben-
eficial effects of enalapril on the hemodynamic aspects of
cardiac filling and output. The current study provides evi-
dence for an additional mechanism of ACE inhibitors to
ameliorate doxorubicin cardiotoxicity via the preservation
of mitochondrial function and down-regulation of free radi-
cal generation. Rats treated with both enalapril and doxoru-
bicin were observed to have higher levels of respiratory
efficiency, minimal depletion of cytosolic ATP, and less ox-
idative stress as compared with animals receiving doxorubi-
cin alone. Enalapril was able to attenuate the harmful effects
of doxorubicin to near control levels in each of these respects
and prevented deterioration in cardiac function and histo-
pathologic grading.
Previous research has suggested that at the subcellular
level, mitochondria may be a primary target of
doxorubicin-induced cardiotoxicity. Specifically, it has
been shown that doxorubicin-treated hearts exhibit mito-
chondrial abnormalities, including a decrease in respiratory
efficiency, inhibition of electron transport complexes, and
disruption of calcium homeostasis.21-23 In accordance with
previous findings, we found that doxorubicin caused
a robust decrease in state 3 respiration, which resulted in
an overall robust decrease in the mitochondrial respiratory
efficiency. The important observation is that enalapril
prevented the decrease in state 4 and, more importantly, in
state 3 oxygen consumption and RCR, thereby maintaining
mitochondrial bioenergetics at normal levels. Similarly, we
found that cellular ATP levels were significantly lowered402 The Journal of Thoracic and Cardiovascular Surgafter doxorubicin treatment, but that enalapril was able to
maintain cellular ATP levels at near control values.
We did not detect any differences among groups in the
amount of basal H2O2 produced and released by isolatedmi-
tochondria respiring with P/M or succinate. However, these
observations in combination with lower RCR and respira-
tion rates of mitochondria isolated from Dox animals rein-
forced the hypothesis that doxorubicin induces ETC
dysfunction (defined as the loss of ETC complex enzymatic
activity or complex content). As support for these ideas,
although basal H2O2 productionwas not different, the calcu-
lated FRL% differed significantly among groups. Specifi-
cally, doxorubicin induced a significant increase in FRL
%, whereas enalapril completely abolished this effect,
maintaining the FRL% at control values. These results dem-
onstrate that enalapril is capable of attenuating the fraction
of electrons flowing out of sequence in the ETC, which ulti-
mately reduce oxygen to form free radicals. In addition to
causing cardiomyocyte dysfunction, generation of O2
 has
also been linked to dysfunction of the coronary vasculature
through inactivation of NO produced by endothelial cells
and formation of ONOO. Reduction in the bioavailability
of NO is significant to the development of heart failure be-
cause the anti-inflammatory and vasodilation properties of
NO are critical to maintaining cardiac function.24,25CONCLUSIONS
This is the first study to assess the effects of ACE inhibi-
tors on mitochondrial bioenergetics and recovery after
chronic doxorubicin treatment. By maintaining the effi-
ciency of mitochondrial respiration and cellular ATP con-
tent to near control levels, our results show that concurrent
treatment with enalapril improves cardiac function in rats
exposed to doxorubicin. Furthermore, the lowered potential
of these mitochondria to produce ROSmay contribute to the
attenuation of dysfunction. Moreover, as has been sug-
gested,15 we also found that cardiomyocyte apoptosis is
only one contributing factor to the decreased cardiac func-
tion during doxorubicin cardiotoxicity. Last, these outcomes
illustrate the importance of maintaining intact mitochon-
drial bioenergetics as a defense mechanism against doxoru-
bicin cardiotoxicity, even in the case when part of the organ
is lost or atrophied. Our findings, in conjunction with recent
clinical reports that early treatment of enalapril after doxo-
rubicin administration prevents development of heart fail-
ure,8,9 support a priori treatment of patients undergoing
anthracycline chemotherapy with ACE inhibitors rather
than after heart failure has been diagnosed.References
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SUPPLEMENTAL MATERIALS AND METHODS
Animals
Twenty-four female Sprague Dawley rats at approximately 10 weeks of age
were obtained fromCharles River Laboratories (Wilmington,Mass). The an-
imals were divided into 3 groups: (1) control-untreated (n ¼ 8), (2) doxoru-
bicin treated (Dox) (n ¼ 8), and (3) Doxþ enalapril treated (DE) (n ¼ 8)
(Figure 1, A). Both Dox and DE groups received doxorubicin at a cumulative
dose of 25 mg/kg administered weekly via intraperitoneal injection for 6
weeks. Enalapril pretreatment for theDEgroupwas started 1weekbefore ad-
ministration of the first doxorubicin injection and continued throughout the
study and for an additional 3 weeks after the last doxorubicin injection. Ena-
lapril was administered in the drinkingwater at a dose of 10mg/kg/d for each
animal as described in previous studies.E1 Body weights were recorded at 2
time points: at 5 weeks from enalapril administration (midpoint) and at 10
weeks (end point). Hearts were explanted and weighed at the end point
(Figure E1).
Assessment of Left Ventricular Fractional
Shortening
For echocardiographic measurement of ventricular function, animals
were knocked down using 1% isoflurane and anesthesia was maintained
with inhaled isoflurane (1%). Echocardiographicmeasureswere conducted
on a short-axis plane, and M-mode was used for the final measurements of
fractional shortening. The mean heart rate was measured during the proce-
dure. Baseline echocardiograms were conducted in all animals before treat-
ment. Echocardiography studies were performed at baseline before
treatment with doxorubicin and immediately before animal sacrifice, using
a 14.7-MHz transducer on a Sequoia C512 echocardiography system
(Siemens, Malvern, Pa). The left ventricular end-diastolic diameter and
end-systolic diameter were measured by a blinded investigator and
processed to calculate left ventricular fractional shortening by the formula:
LVFS ¼ [EDD–ESD]/EDD, where LVFS is left ventricular fractional
shortening, EDD is end-diastolic diameter, and ESD is end-systolic
diameter.
Postmortem Histology
At the time of death, a subset of the animal hearts and livers was
fixed in 4% paraformaldehyde, subsequently cut, and embedded in par-
affin blocks. The blocks were then sectioned into short-axis slices,
which were subsequently stained with hematoxylin–eosin stain accord-
ing to standard protocols. High-power fields of the sections were photo-
graphed.
Mitochondrial and Cytosolic Isolation
Mitochondrial and cytosolic protein fractions were isolated using differ-
ential centrifugation. Specifically, at the end of the study period, animals
were anesthetized using isoflurane gas. When a general plane of anesthesia
was reached, the chest was opened and the heart was excised, cleaned with
phosphate-buffered saline, and weighed. The heart was finely minced into
small pieces and homogenized in (1:8 wt/vol) ice-cold isolation buffer con-
taining 220 mmol/L mannitol, 70 mmol/L sucrose, 1 mmol/L EDTA, 10
mmol/LTris, and 0.2% fatty acid free bovine serum albumin, pH 7.4, using
a Potter-Elvehjem glass homogenizer (Glas-Col LLC, Terre Haute, Ind).
The homogenate was centrifuged at 700g for 10 minutes. Part of the super-
natant was used immediately for the measurement of ATP content, and the
remaining supernatant was then centrifuged at 8000g for 10 minutes. The
supernatant (crude cytosol) was stored at80C for further analysis, and
themitochondrial pellet was resuspended in 200mLof isolation buffer with-
out bovine serum albumin and used immediately for the measurements of
mitochondrial H2O2 production and oxygen consumption. All centrifuga-
tion steps were carried out at 4C. Protein concentrations were determined
using the Bradford method.E2
EnzymaticMeasurement of Caspase-3 and Caspase-9
Activities
Heart cytosolic fractions were prepared and caspase-3 and caspase-9
activities were measured using fluorometric protease assay kits: Caspase-
3/CPP32 and Caspase-9/Mch6 (Biovision, Mountain View, Calif) accord-
ing to the manufacturer’s instructions. Briefly, in these assays, the sub-
strates DEVD-AFC and LEHD-AFC are cleaved by caspase-3 and -9
respectively, releasing free AFC emitting a yellow-green fluorescence (l
max ¼ 505 nm) that is quantified using a fluorescence microtiter plate
reader. Samples were run in triplicate, and values were expressed as raw
fluorescence units per milligram of cytosolic protein.
Mitochondrial Respiration
Mitochondrial oxygen consumption was measured at 37C by polarogra-
phy, with a Clark-type oxygen electrode (Oxytherm, Hansatech, Norfolk,
UK) under identical conditions (same mitochondria, buffer composition,
and substrate concentrations) to H2O2 production measurements: incubation
buffer (145 mmol/L KCl, 30 mmol/L Hepes, 5 mmol/L KH2PO4, 3 mmol/L
MgCl2, 0.1 mmol/L EGTA, pH 7.4) with 1 mg of mitochondrial protein per
milliliter and 2.5 mmol/L pyruvate/2.5 mmol/L malate as substrates. The as-
saywas performed in the absence (state 4: resting state) and presence (state 3:
phosphorylating state) of 500 mmol/L ADP. Clark-type electrode without
(state 4) and with saturant ADP (state 3) allows calculation of the RCR (state
3/state 4 oxygen consumption) as an indicator of the degree of coupling and
metabolic activity of the mitochondrial preparations.
Adenosine Triphosphate Content
Mitochondria and homogenate isolated from heart were used immedi-
ately after isolation to determine ATP content using a bioluminescence
ATP kit from Sigma-Aldrich Inc (St Louis, sMO), following the manufac-
turer’s protocol. This bioluminescence assay is based on the reaction of
ATP with recombinant firefly luciferase and its substrate D-Luciferin. On
addition, ATP combines with Luciferin to form luciferyl adenylate and in-
organic pyrophosphate on the surface of the luciferase enzyme. While
bound to the enzyme, luciferyl adenylate combines with O2 to form oxylu-
ciferin and AMP through a series of enzymatic redox reactions. As oxylu-
ciferin and AMP are released from the enzyme’s surface, a quantum yield
of light is emitted in proportion to the ATP concentration in the sample. The
light emission can then be recorded and quantified using a chemiluminom-
eter. Mitochondria and homogenates were suspended in a lysis buffer for 3
minutes, followed by the addition of the reaction mixture containing lucif-
erase and luciferin. ATP content was measured with a Packard LumiCount
luminometer (Packard, United Kingdom), using an ATP standard curve.
Final mitochondrial and homogenate concentrations used in the assay
were 1 mg/mL.
Mitochondrial H2O2 Generation
The rate of mitochondrial H2O2 production was assayed in freshly iso-
lated mitochondria by a highly sensitive fluorometric method according to
BarjaE3 and adapted to a microplate reader. H2O2 generationwasmonitored
bymeasuring the increase in fluorescence (excitation at 312 nm, emission at
420 nm) due to the oxidation of homovanillic acid by H2O2 in the presence
of horseradish peroxidase. The assay was performed in incubation buffer
(145 mmol/L KCl, 30 mol/L Hepes, 5 mmol/L KH2PO4, 3 mmol/L
MgCl2, 0.1 mmol/L EGTA, 0.2% bovine serum albumin, pH 7.4) at
37C, and the reaction conditions were 0.25 mg of mitochondrial protein
per mL, 6 U/mL of horseradish peroxidase, and 0.1 mmol/L homovanillic
acid. The reaction was started by the addition of 2.5 mmol/L pyruvate/
2.5 mmol/L malate, or 5 mmol/L succinate as substrates. P/M was used to
study total basal ROS production, and succinate was used to study complex
III ROS production under basal conditions as described previously.E4 After
15 minutes of incubation at 37C, the reaction was stopped and the samples
were transferred on ice and a stop solution (0.1 mol/L glycine, 25 mmol/L
Evolving Technology/Basic Science Hiona et al
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EDTA, pH 12)was added. Known amounts of H2O2 generated in parallel by
glucose oxidase, with glucose as substrate, were used as standards. We also
used inhibitors of theETC to studymaximumrates ofH2O2 production from
complexes I and III, because they represent themain sites ofROSgeneration
(especially complex I) within the mitochondria. For complex I maximum
rate, we used 2mmol/L rotenone added to P/M-supplementedmitochondria.
For complex IIImaximum rate, we used 2 mmol/L antimycinA plus 2mmol/
L rotenone added to succinate-supplemented mitochondria. In addition, the
assayswith succinate as substratewere performed in the presence of 2mmol/
L rotenone to avoid the backward flowof electrons to complex I.All samples
were run in duplicate. H2O2 production andO2 consumptionweremeasured
in parallel in the same heart mitochondria under similar experimental con-
ditions. This allowed the calculation of the fraction of electrons out of se-
quence that reduce O2 to ROS at the respiratory chain (FRL%) instead of
reaching cytochrome oxidase to reduce O2 to water. Because 2 electrons
are needed to reduce 1 mole of O2 to H2O2 and 4 electrons are transferred
in the reduction of 1 mole of O2 to water, the FRL% can be calculated as
the rate of H2O2 production divided by 2 times the rate of O2 consumption,
and the result is multiplied by 100.
SUPPLEMENTAL RESULTS
Animal Survival, Body Weight, and Heart Mass
There were no deaths in the control and DE groups
(100% survival) during the experimental protocol. How-
ever, 2 rats from the Dox group died of heart failure during
weeks 9 and 10 (75% survival; log-rank Mantel–Cox test:
P ¼ .11; NS compared with control and DE; Figure 1, B).
Body weights were recorded at 2 time points: at 5 weeks
into the study (midpoint) and at 10 weeks (end point)
(Figure E1, A). Heart weights were recorded immediately
after heart extraction at end point (Figure E1, B). There
was a significant decrease in body weight in both the Dox
(237.1  6.7 g) and DE (215.8  5.5 g) groups compared
with the control rats (278.1  10.2 g) at week 5 (both
P<.05; Figure E1, B). By week 10, total body weight de-
creased for both the Dox (196.9  11.9 g) and DE (208 
9.73 g) groups compared with control rats (287.8  12.64
g) (both P<.05). Heart weight diminished significantly in
the Dox (0.52  0.03 g) and DE (0.52  0.025 g) groups
compared with control (0.78  0.019 g) at week 10 (both
P<.05; Figure E1, B), indicative of heart damage and pos-
sible cardiomyocyte apoptosis. It is evident that doxorubi-
cin treatment resulted in significant body mass and heart
mass losses that were not prevented by enalapril administra-
tion. As expected, the body weight to heart weight ratio did
not differ significantly among the groups (control: 0.0028
0.0001 vs Dox: 0.0027  0.0001 vs DE: 0.0025  6.230)
because both heart weight and body weight were decreased
by doxorubicin to the same proportion, resulting in stable
ratios.
Baseline Echocardiographic Measures and Heart
Rate for Assessment of Cardiac Function
The mean heart rate for all animals during the echocar-
diographic procedure was 410  20 beats/min at baseline
before treatment with doxorubicin and 405  15 beats/
min at the study end point (P¼NS). Therewas no statistical
difference between the control DOX and DE groups. In
addition, fractional shortening values calculated at baseline
were not significantly different from the control group’s
values at study end (baseline of all animals before Dox
treatment: 38.62  0.77, control group at study end:
39.28  0.83).
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FIGUREE1. Doxorubicin treatment induces a significant loss of body mass and heart mass in both Dox and DE groups. A, Body weights were recorded at
5 weeks into the study (midpoint) and at 10 weeks (end point). B, Heart weights were recorded on heart extraction at end point. The heart weight to total body
weight ratio was also calculated. Error bars represent SEM. *P<.05. *Significantly different compared with Dox and DE groups. Dox, Doxorubicin; DE,
doxorubicinþenalapril.
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